The Discounted Cash Flow (DCF) valuation of Halozyme Therapeutics Inc (HALO) is 78.96 USD. With the latest stock price at 56.58 USD, the upside of Halozyme Therapeutics Inc based on DCF is 39.5%.
Based on the latest price of 56.58 USD and our DCF valuation, Halozyme Therapeutics Inc (HALO) is a buy. buying HALO stocks now will result in a potential gain of 39.5%.
| Range | Selected | |
| WACC / Discount Rate | 7.1% - 9.0% | 8.1% |
| Long-term Growth Rate | 0.5% - 1.5% | 1.0% |
| Fair Price | 64.68 - 100.45 | 78.96 |
| Upside | 14.3% - 77.5% | 39.5% |